IAN8 Antibody

Molecular Design and Antigenic Basis

IAN8 is a computationally optimized broadly reactive antigen (COBRA) designed using H5 HA sequences from 4,524 avian and human influenza viruses collected between 2011–2017 . Its purpose is to elicit antibodies against conserved epitopes across H5N1 clades.

Key features of IAN8 HA:

• Subtype: H5 (avian-origin influenza A)

• Target strains: Includes A/Vietnam/1203/2004 (H5N1) and other zoonotic H5 viruses .

• Design strategy: Optimized via phylogenetic analysis to maximize cross-reactivity .

Antibody Response in Preclinical Studies

In ferret models vaccinated with the octavalent COBRA vaccine (containing IAN8), robust antibody responses were observed:

• Statistical significance: Vaccinated groups showed P < 0.0001 increases in H5 HA-specific IgG compared to mock controls .

• Cross-protection: Antibodies neutralized H5N1 (A/Vietnam/1203/2004) in challenge studies, reducing viral shedding by >90% (P < 0.05) .

Functional Mechanisms

• Broad reactivity: Antibodies target conserved regions of H5 HA, preventing viral entry into host cells .

• Immune memory: Vaccination induced long-lived plasma cells and memory B cells, critical for rapid recall responses .

Comparative Efficacy in Challenge Models

Post-vaccination challenge with H5N1 yielded the following results:

• Histopathology: Minimal lung inflammation in vaccinated ferrets vs. severe alveolar damage in controls .

Clinical Relevance and Future Directions

While IAN8-specific antibodies have not yet entered human trials, the COBRA platform has demonstrated:

• Pan-H5 coverage: Potential to address antigenic drift in avian influenza viruses .

• Synergy with other components: The octavalent formulation includes H1, H3, H7, and neuraminidase targets, enabling multi-subtype protection .